Holen Sie sich die Stockscreener-App
579.23
2.89%
16.26
Vorhandelsmarkt:
576.40
-2.83
-0.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$562.97
Offen:
$561.85
24-Stunden-Volumen:
665.11K
Relative Volume:
1.23
Marktkapitalisierung:
$45.69B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$1.06B
KGV:
44.28
EPS:
13.0798
Netto-Cashflow:
$1.04B
1W Leistung:
+4.62%
1M Leistung:
+0.31%
6M Leistung:
-18.85%
1J Leistung:
+22.28%
1-Tages-Spanne:
$550.45
$580.65
1-Wochen-Bereich:
$548.07
$584.72
52-Wochen-Spanne:
$471.74
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
579.23 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
TMO
Thermo Fisher Scientific Inc
|
472.95 | 175.76B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.92 | 123.80B | 24.78B | 3.68B | 5.29B | 5.1743 |
WAT
Waters Corp
|
349.53 | 34.31B | 3.77B | 449.25M | 516.49M | 8.7322 |
A
Agilent Technologies Inc
|
117.69 | 33.26B | 7.07B | 1.29B | 993.00M | 4.5355 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $729 - Moomoo
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call - Sahm
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2026 Earnings Call Transcript - Insider Monkey
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Maintains Target Price $805 - 富途牛牛
Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 - marketscreener.com
BofA cuts Idexx Laboratories stock price target on macro concerns By Investing.com - Investing.com South Africa
IDEXX (NASDAQ: IDXX) lifts Q1 profit and ramps up buybacks - Stock Titan
BofA cuts Idexx Laboratories stock price target on macro concerns - Investing.com
BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $660 - 富途牛牛
IDEXX Laboratories Q1 Earnings Call Highlights - Yahoo Finance
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
IDEXX Laboratories, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IDXX) 2026-05-05 - Seeking Alpha
IDEXX Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
IDEXX Q1 2026 slides: raised guidance on strong diagnostic growth - Investing.com
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up - Yahoo Finance
Earnings call transcript: IDEXX Labs exceeds Q1 2026 forecasts, stock rises - Investing.com UK
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency - Benzinga
IDEXX beats expectations on Q1 results, raises 2026 outlook - Mainebiz
Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally? - Yahoo Finance
IDEXX Laboratories Releases Q1 2026 Financial Results - AlphaStreet
IDEXX Laboratories Q1 Comparable Earnings, Revenue Rise - marketscreener.com
MSN Money - MSN
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
IDEXX Laboratories (NASDAQ:IDXX) Beats and Raises on Strong Demand, Sending Shares Up - ChartMill
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 Comparable EPS $3.30, vs. FactSet Est of $3.39 - marketscreener.com
IDEXX LABS ($IDXX) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q1 Revenue $1.14B, vs. FactSet Est of $1.12B - marketscreener.com
IDEXX Laboratories : Earnings snapshot Q1 2026 - marketscreener.com
Idexx: Q1 Earnings Snapshot - KVUE
IDEXX posts Q1 revenue $1.141B, EPS $3.47; raises 2026 revenue and EPS outlook - TradingView
Idexx Laboratories, Inc. Raises Earnings Guidance for the Full Year 2026 - marketscreener.com
Long-Term Leaders: Boston Scientific Joins Watchlist, Motorola Out - Investor's Business Daily
IDEXX Laboratories Q1 2026 earnings preview - MSN
IDEXX (NASDAQ: IDXX) director defers $24,375 into stock units - Stock Titan
IDEXX earnings up next as softer vet visits cloud Q1 expectations By Investing.com - Investing.com South Africa
IDEXX earnings up next as softer vet visits cloud Q1 expectations - Investing.com Nigeria
IDEXX Laboratories (IDXX) Investor Outlook: Unpacking A 27.67% Upside Potential - DirectorsTalk Interviews
What you need to know ahead of IDEXX Laboratories' earnings release - MSN
IDEXX Laboratories, Inc. $IDXX Stock Position Lifted by Danske Bank A S - MarketBeat
IDEXX Laboratories Inc | SCHEDULE 13G: Others - Moomoo
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings - Yahoo Finance
Oppenheimer Asset Management Inc. Raises Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Vanguard Capital Management (IDXX) reports 5.98M shares, 7.51% stake - Stock Titan
IDEXX Laboratories, Inc. $IDXX Stake Boosted by Wealthfront Advisers LLC - MarketBeat
IDEXX Laboratories Stock (US45168D1046): Set to Report Q1 2026 Earnings - AD HOC NEWS
UBS Group AG Has $192.78 Million Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Neuberger Mid Cap Growth Fund's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Experiences Valuation Adjustment Amid Strong Financial Indicators - Markets Mojo
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
How Idexx Laboratories Inc. (IDXX) Affects Rotational Strategy Timing - Stock Traders Daily
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):